Preprint paper: Effect of Convalescent Plasma on Hospitalized Patients with COVID-19: Initial Three-Month Experience
Mayo Clinic researchers and collaborators have published a preprint that identifies two main signals of efficacy that can inform future clinical trials on plasma therapy for COVID-19 patients. The data are extracted from the Mayo-led national Expanded Access Program (EAP) for convalescent plasma for the treatment of hospitalized patients with COVID-19. Specifically:
- Convalescent plasma signals of efficacy are associated with reduced COVID-19 mortality in 35,000-plus patients.
- The seven-day mortality rate was reduced in patients transfused within three days of COVID-19 diagnosis compared with patients transfused four or more days after COVID-19 diagnosis. Similar trends were seen for 30-day mortality rate.
- The use of convalescent plasma with higher antibody levels was associated with reduced seven-day and 30-day mortality.
- This update includes adult participants enrolled in the national EAP between April 4 and July 4 who were hospitalized with (or at risk of) severe or life-threatening acute COVID-19 respiratory syndrome.
- The cohort included a high proportion of critically ill patients, with 52.3% in the intensive care unit (ICU) and 27.5% receiving mechanical ventilation at the time of plasma transfusion.